PT-141

PT-141, known generically as bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan 2 (MT-2). Its development emerged from an unexpected observation during early MT-2 clinical trials: the majority of male subjects reported spontaneous erections following administration. Researchers isolated the central nervous system mechanism responsible for this effect and developed a more targeted compound. Unlike MT-2, PT-141 is a cyclic peptide without the full melanocortin receptor activity profile of its predecessor, and it does not produce significant skin tanning under normal use conditions.

PT-141 is a selective agonist at the melanocortin MC3R and MC4R receptors, which are expressed primarily within the central nervous system rather than at the genital tissue itself. This mechanism of action fundamentally distinguishes PT-141 from all prior treatments for sexual dysfunction. PDE5 inhibitors (sildenafil, tadalafil) and vasodilators act peripherally on genital blood flow. PT-141 acts centrally, on the neural circuits governing sexual desire and arousal within the brain itself. When PT-141 binds to MC4R in the hypothalamus and related limbic structures, it stimulates the release of dopamine and related neurochemicals involved in motivation and reward, effectively activating the brain's wanting and approach circuitry for sexual activity. This is why the compound can benefit individuals with low desire rather than solely vascular dysfunction.

In 2019, the FDA approved bremelanotide under the brand name Vyleesi as an on-demand subcutaneous injection for premenopausal women with hypoactive sexual desire disorder (HSDD). This marked a milestone: the first centrally acting, non-hormonal pharmacological treatment approved specifically for sexual desire in women. The pivotal Phase 3 trials (RECONNECT studies) demonstrated statistically significant improvements in sexual desire scores and reductions in distress related to low desire compared to placebo. The responder rate in these trials was approximately 25 percent of treated women versus 17 percent in the placebo group, reflecting real but modest clinical benefit at the 1.75 mg approved dose.

Off-label use of PT-141 in men is widespread and growing. Clinical data supporting efficacy in male sexual dysfunction are more limited than for women but consistent. Published studies and clinical observations suggest PT-141 is effective for erectile dysfunction, particularly in men who do not respond to or cannot tolerate PDE5 inhibitors, and in men whose dysfunction has a desire or psychogenic component rather than a purely vascular origin. The compound may augment the effect of PDE5 inhibitors when used in combination, though this approach has not been formally evaluated in large controlled trials.